EDITAS MEDICINE, INC. Notes Payable
EDITAS MEDICINE, INC. (EDIT) had Notes Payable of $7.50 million as of 2017-12-31, per its 10-K filed 2019-03-01.
Discontinued › Balance Sheet › Liabilities
us-gaap:NotesPayable · last filed 2019-03-01
- 2017-12-31: Notes Payable $7.50M.
- 2017-06-30: Notes Payable $15.00M.
- 2017-03-31: Notes Payable $15.00M.
- 2016-12-31: Notes Payable $10.00M.
| Period end | Notes Payable |
|---|---|
| 2017-12-31 | $7.50M 10-K · filed 2019-03-01 |
| 2017-06-30 | $15.00M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $15.00M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $10.00M 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |